RxDoctor Payments DataLook up a doctor →

Mohsin Alhaddad, MD

Cardiovascular Disease · Jackson, TNNPI 1467624619

Payments from drug & device makers

$1,807,449in general payments, 2019–2025

Across 1,037 payments — averaging $1742.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1M
  • Janssen Research & Development, LLC$277K
  • Boehringer Ingelheim International GmbH$169K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$121K
  • Merck$102K
  • Bayer$39K
  • plus $52K from 45 others
$1,220in research payments, 2019–2025

Across 2 payments — averaging $609.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,807,449 in reported general payments places this provider in the 95th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$1,030,578
Medicare patients
1,273
Services billed
7,933

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Jackson

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →